London, UK – 28 November 2018: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, is delighted to have been shortlisted for the Best Technological Development in Clinical Trials category at the 14th Annual SCRIP Awards. Ergomed’s PrimeVigilance is being recognised for the promising and […]
London, UK – 28 November 2018: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, is delighted to have been shortlisted for the Best Technological Development in Clinical Trials category at the 14th Annual SCRIP Awards.
Ergomed’s PrimeVigilance is being recognised for the promising and transformative role that its robotic process automation (RPA) system plays in clinical drug development. As a thought leader, PrimeVigilance has started early deployment of robotic process automation in pharmacovigilance. By 2020, automation is likely to reduce manual case processing efforts by over 80%. The system can increase efficiency by up to 400 times, increasing speed, reducing cost and improving accuracy in clinical trials. This positions Ergomed at the forefront of pharmacovigilance services.
The awards ceremony will be held at the Hilton on Park Lane, London tonight.
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 503205 | |
| Stephen Stamp (Chief Executive Officer) | ||
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
| Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
| James Black (Joint Broker) | ||
| Consilium Strategic Communications – for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
| Chris Gardner / Mary-Jane Elliott
Matthew Neal / Olivia Manser |
ergomed@consilium-comms.com | |
| MC Services – for Continental European enquiries | Tel: +49 211 5292 5222 | |
| Anne Hennecke | ||
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: https://ergomedgroup.com
